Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

After-tax profit was 812 million euros compared with 740 million in the same period last year, Merck said Thursday. The ...

Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

There is already much Australian interest in purchasing one of the suites on Ulyssia, which range in price from €10m to €100m ...